미국의 위암 진단 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 제품별, 질환 유형별, 최종 용도별, 부문 예측(2025-2033년)

U.S. Gastric Cancer Diagnostics Market Summary

The U.S. gastric cancer diagnostics market size was estimated at USD 489.09 million in 2024 and is projected to reach 897.20 million by 2033, and growing at a CAGR of 7.08% from 2025 to 2033. The U.S. gastric cancer diagnostics market is expanding due to advancements in diagnostic technologies, increasing awareness and patient education, and the expansion of healthcare infrastructure in emerging markets. According to the American Cancer Society (ACS) in 2024, gastric cancer accounted for 26,890 new cases and 10,880 deaths in the U.S. In addition, 30,300 new cases and 10,780 deaths are estimated in the U.S. for the year 2025.

Technological innovations such as liquid biopsies, next-generation sequencing (NGS), and AI-based imaging are propelling the market growth. These tools enable early detection, improved staging, and better characterization of tumor biology, leading to more personalized and effective treatment plans. Advanced endoscopy techniques, like narrow-band imaging and confocal laser endomicroscopy, enhance diagnostic accuracy and patient outcomes. Integration of molecular diagnostics also allows for targeted therapies based on genetic profiles. As healthcare providers and researchers push for more precise, less invasive methods, technological progress boosts market demand, offering faster results, better sensitivity, and reduced patient discomfort compared to traditional methods.

Public awareness campaigns and educational initiatives led by governments, NGOs, and healthcare providers are further fueling market growth by improving recognition of gastric cancer symptoms and risk factors. One such example is Hope for Stomach Cancer, a national nonprofit organization that will play a key role at the May 2025 ASCO Annual Meeting, advancing early detection, treatment, and awareness of stomach and gastroesophageal cancers through advocacy, education, patient support, and national legislative partnerships. This increased awareness is prompting earlier medical consultations and higher participation in screening programs. Moreover, the rise in health literacy and access to online medical information empowers patients to seek timely diagnosis and appropriate care. As patients and caregivers become more proactive, the demand for accurate and accessible diagnostic services grows. This trend is vital in emerging economies, where awareness efforts are narrowing the gap in healthcare utilization and fueling market growth for diagnostic technologies.

The expansion of healthcare infrastructure associated with developing nations is one of the drivers in the U.S. gastric cancer diagnostics market through a different lens, namely, health equity and outreach. In the U.S., ongoing investments in healthcare infrastructure, especially in underserved and rural areas, are improving access to diagnostic services, including endoscopy and advanced imaging for gastric cancer. Federally funded programs and hospital network expansions aim to bridge disparities, enabling earlier detection and better outcomes in high-risk populations such as Asian American and Hispanic communities, where gastric cancer prevalence is comparatively higher. These efforts support market growth by increasing demand for diagnostic tools.

U.S. Gastric Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. gastric cancer diagnostics market report based on product, disease type, end use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Reagents & Consumables
• Instruments
• Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
• Adenocarcinoma
• Gastric lymphoma
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Diagnostic Laboratories
• Diagnostic imaging

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Disease Type
  • 1.2.3. End use
  • 1.2.4. Country scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Disease type outlook
  • 2.2.3. End use outlook
  • 2.2.4. Country outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Gastric Cancer Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Gastric Cancer Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Gastric Cancer Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2024 & 2033
• 4.2. Segment Dashboard
• 4.3. U.S. Gastric Cancer Diagnostics Market: Product Movement Analysis
• 4.4. U.S. Gastric Cancer Diagnostics Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
• 4.5. U.S. Gastric Cancer Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Reagents & consumables
  • 4.6.1. Reagents & consumables Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Instruments
  • 4.7.1. Instruments Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Gastric Cancer Diagnostics Market: Disease Type Estimates & Trend Analysis

• 5.1. Disease Type Market Share, 2024 & 2033
• 5.2. Segment Dashboard
• 5.3. U.S. Gastric Cancer Diagnostics Market by Disease Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Adenocarcinoma
  • 5.5.1. Adenocarcinoma Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Gastric lymphoma
  • 5.6.1. Gastric lymphoma Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. Gastric Cancer Diagnostics Market: End use Estimates & Trend Analysis

• 6.1. End use Market Share, 2024 & 2033
• 6.2. Segment Dashboard
• 6.3. U.S. Gastric Cancer Diagnostics Market by End use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Hospitals
  • 6.5.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Diagnostic Laboratories
  • 6.6.1. Diagnostic Laboratories Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Diagnostic imaging
  • 6.7.1. Diagnostic imaging Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. U.S. Gastric Cancer Diagnostics Market: Country Estimates & Trend Analysis

• 7.1. Country Market Share Analysis, 2024 & 2033
• 7.2. Country Market Dashboard
• 7.3. U.S. Country Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.5. U.S.
  • 7.5.1. Key country dynamics
  • 7.5.2. Regulatory framework/Reimbursement
  • 7.5.3. Competitive scenario
  • 7.5.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Illumina, Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Guardant Health
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Natera, Inc
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. GE Healthcare.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Thermo Fisher Scientific Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. QIAGEN
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Freenome Holdings Inc
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Exact Sciences Corporation
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. PathAI
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives